氟伐他汀在中、重度慢性持续期支气管哮喘治疗中的作用观察

Observation on Effect of Fluvastatin in the Treatment of Moderate and Severe Chronic Persistent Bronchial Asthma

目的探讨氟伐他汀在中、重度慢性持续期支气管哮喘治疗中的应用效果。方法选取该院2017年4月—2018年5月期间收治的中、重度慢性持续期支气管哮喘患者54例为研究对象,随机分为两组,对照组实施常规治疗,观察组在对照组的基础上应用氟伐他汀,对比两组治疗情况。结果治疗前,观察组的FEV1、FEF为(61.72±3.54)%、(279.56±7.25)L/min,对照组为(61.73±3.53)%、(279.57±7.24)L/min,组间比较,差异无统计学意义(t=0.512 6、0.542 6,P>0.05);治疗后,观察组的FEV1、FEF为(82.32±1.24)%、(365.84±4.35)L/min,对照组为(73.14±2.12)%、(317.56±6.42)L/min,两组的FEV1、FEF高于治疗前,观察组高于对照组,差异有统计学意义(t=5.325 4、5.268 4,P<0.05);治疗前,观察组的TNF-α、IL-6、IL-10为(1.52±0.33)ng/L、(372.32±54.26)ng/L、(20.54±3.42)ng/L;对照组为(1.53±0.34)ng/L、(372.34±54.23)ng/L、(20.55±3.44)ng/L,组间比较,差异无统计学意义(t=0.562 5、0.542 8、0.572 5,P>0.05);治疗后,观察组的TNF-α、IL-6、IL-10为(0.92±0.21)ng/L、(94.56±15.24)ng/L、(31.23±4.26)ng/L;对照组为(1.25±0.32)ng/L、(193.24±45.26)ng/L、(24.56±3.58)ng/L,两组的TNF-α、IL-6低于治疗前,IL-10高于治疗前,观察组的TNF-α、IL-6低于对照组,IL-10高于对照组,差异有统计学意义(t=5.326 8、5.424 6、5.287 4,P<0.05)。结论氟伐他汀在中、重度慢性持续期支气管哮喘治疗中的应用效果显著,肺部功能得到改善,提高了治疗效果,值得应用。

Objective To study the application effect of fluvastatin in the treatment of moderate and severe chronic persistent bronchial asthma. Methods 54 cases of patients with moderate and severe chronic persistent bronchial asthma admitted and treated in our hospital from April 2017 to May 2018 were selected and randomly divided into two groups, the control group used the routine therapy, while the observation group used the fluvastatin on the basis of the control group, and the treatment conditions were compared between the two groups. Results Before treatment, the FEV1, FEF in the observation group and in the control group were respectively（61.72±3.54）%, （279.56±7.25）L/min and （61.73±3.53） %, （279.57±7.24） L/rain, and the differences were not statistically significant t=0.5126, 0.5426, P〉0.05, after treatment, the FEV1, FEF in the observation group and in the control group were respectively （82.32±1.24）%, （365.84±4.35） L/rain and （73.14±2.12） %, （317.56±6.42） L/rain, and the indicators in the observation group were higher than those in the control group, and the differences were statistically significant （t=5.325 4,5.268 4, P〈0.05） ;before treatment, the TNF-cq IL-6, IL-10 in the observation group and in the control group were respectively （1.52±0.33）ng/L, （372.32±54.26）ng/L, （20.54±3.42）ng/L and （1.53±0.34）ng/L, （372.34±54.23）ng/L, （20.55±3.44）ng/L, and the differences were not statistically significant （t=0.562 5, 0.542 8, 0.572 5, P〉 0.05）;after treatment, the TNF-α, IL-6, IL-10 in the observation group and in the control group were respectively （0.92±0.21）ng/L,（94.S6±15.24）ng/L, （31.23±4.26）ng/L and （1.25±0.32）ng/L, （193.24±45.26）ng/L, （24.56±3.58）ng/L, and the TNF-α IL-6 of the two groups were lower than those before treatment, the IL-10 was higher than that in the control group, and the differences were statistically significant （ t=5.326 8,5.424 6,5.287 4, P〈0.05） . Conclusion The application effect of fluvastatin in the treatment of moderate and severe chronic persistent bronchial asthma is obvious, which can improve the lung function and improve the treatment effect, and it is worth application.